Roth Capital Remains Positive On TG Therapeutics Following Discussions With Management
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $25 price target.
Pantginis said, “Discussions with management have indicated what we consider to be significant and impressive cost efficiencies for the upcoming Phase III combination study (under SPA) with TG-1101 and Imbruvica in CLL patients. This ~330 patient study is expected to cost in the $10-15 million range whereas other Phase III oncology studies could easily have cost in the $30-35 million range.”
The analyst continued, “We believe that TGTX is in control of whether the company wants to partner its products or not. It has already shown the ability to form fruitful alliances such as with Pharmacyclics’ (NASDAQ:PCYC) Imbruvica and the ongoing combo study with TG-1101. Management has commented previously that the company would like to hold onto the drugs for as long as possible, and possibly not partner at all. However, given the favorable terms that Infinity (NASDAQ:INFI) secured in the deal with AbbVie (NASDAQ:ABBV) for its PI3K inhibitor and given TGTX’s clinical data to date, we believe TGTX would have significant leverage if it chose to pursue a partnership.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -6.7% and a 35.6% success rate. Pantginis has a 13.8% average return when recommending TGTX, and is ranked #3248 out of 3284 analysts.